Summary: Myriad Genetics, Inc.

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Highlights: Myriad Genetics, Inc.

  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses: Myriad Genetics, Inc.

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Myriad Genetics, Inc.

Source: Surperformance

ESG chart: Myriad Genetics, Inc.

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
- 1.19B
13.89B
6.83B
5.5B
- 3.19B
2.46B
Average 5.51B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
A

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health
-

Valuation

P/E ratio
-
EV/REVENUE
EV/EBITDA
PBR
Yield
-

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. Ratings Myriad Genetics, Inc.